Compounded vs. Brand GLP-1s: The Complete Guide
Brand-name Wegovy costs ~$1,350/month. Compounded semaglutide can cost as little as $200/month. The price gap created one of the largest gray markets in pharmaceutical history — and now the FDA is cracking down. Here's everything you need to know.
The Core Trade-Off at a Glance
Brand-Name GLP-1s
- ✅ FDA-approved, clinical trial data
- ✅ Standardized purity and dosing
- ✅ Manufacturer safety monitoring
- ❌ ~$1,000–1,500/month without insurance
- ❌ Frequent supply shortages historically
Compounded GLP-1s
- ✅ ~$200–400/month significantly cheaper
- ✅ Wider telehealth access
- ❌ Not FDA-approved, no clinical trials
- ❌ Quality and purity varies by pharmacy
- ❌ Legal status changing rapidly
Table of Contents
What Are Compounded GLP-1s?
Compounded GLP-1s are copies of brand-name medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) made by compounding pharmacies rather than the original manufacturers.
Compounding is a legal pharmaceutical practice where pharmacists combine, mix, or alter ingredients to create customized medications. It has long been used to:
- Create medications not commercially available (e.g., a pediatric liquid form of an adult pill)
- Remove allergens (dyes, preservatives) for sensitive patients
- Adjust doses that aren't available in standard commercial forms
- Fill supply gaps during FDA-declared drug shortages
The GLP-1 compounding boom happened primarily because of the third reason: the FDA declared both semaglutide and tirzepatide in shortage status, which under federal law allows compounding pharmacies to legally produce copies of those medications.
- 503A pharmacies — Traditional pharmacies that compound on a prescription-by-prescription basis. Less oversight, but legal for individual patients.
- 503B outsourcing facilities — Larger-scale facilities registered with the FDA, subject to cGMP inspections. Higher quality standards, but not FDA approval for specific products.
FDA's Position on Compounded GLP-1s
The FDA's stance on compounded GLP-1s has shifted dramatically and continues to evolve. Understanding this timeline is essential:
GLP-1 shortage declarations
The FDA placed semaglutide and tirzepatide on the drug shortage list as demand far exceeded supply. This legally enabled compounding pharmacies to produce copies.
Compounding market explodes
Thousands of compounding pharmacies — and telehealth platforms like Hims, Ro, and Found — began offering compounded semaglutide and tirzepatide at dramatically lower prices.
FDA resolves semaglutide shortage
The FDA removed semaglutide from its shortage list, triggering enforcement actions. The agency issued cease-and-desist letters to compounders and set compliance deadlines for 503B facilities.
Enforcement, lawsuits, and warning letters
The FDA issued over 135 warning letters to compounders and telehealth platforms. Eli Lilly filed civil suits against several compounders. A federal court upheld the tirzepatide shortage removal in Outsourcing Facilities Association v. FDA (May 2025). The Outsourcing Facilities Association also challenged the semaglutide removal but lost at the district level.
FDA proposes permanent closure of 503B bulk compounding for GLP-1s
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs. If finalized, this would permanently end large-scale 503B compounding regardless of future shortage status. Public comment period closes June 29, 2026.
Current FDA stance (May 2026):
The FDA considers mass-scale compounded semaglutide unlawful since the shortage resolved in February 2025. The same applies to tirzepatide since October 2024. A proposed rule published April 30, 2026 would permanently exclude both drugs from the 503B bulks list on clinical-need grounds, regardless of future shortage status. Any compounded GLP-1 accessed today carries legal and quality risk that did not exist in 2023.
2026 Regulatory Status Tracker
The regulatory situation for compounded GLP-1s is now the most restrictive it has ever been. This section breaks down the current status by drug, by pharmacy type, and by the key legal concepts that determine what remains permissible.
Semaglutide (Wegovy / Ozempic)
- ▸Removed from the FDA shortage list February 21, 2025. The shortage-based legal basis for compounding ended at that point.
- ▸503B outsourcing facilities lost their enforcement-discretion window in early 2025. Large-scale compounding of semaglutide from bulk is no longer legally defensible for 503B facilities.
- ▸503A state-licensed pharmacies may still prepare patient-specific compounds where documented clinical need exists (e.g., allergy to an inactive ingredient, a specific dose not commercially available). Economic need alone does not qualify.
- ▸The April 30, 2026 proposal would formally exclude semaglutide from the 503B bulks list. If finalized, no future shortage declaration would reopen the 503B pathway without a new rulemaking.
Tirzepatide (Zepbound / Mounjaro)
- ▸FDA declared the tirzepatide shortage resolved in October 2024. The 503B enforcement-discretion period ended March 19, 2025. Mass compounding by outsourcing facilities became unlawful at that point.
- ▸The Outsourcing Facilities Association challenged the shortage removal in federal court. A district court upheld the FDA decision in May 2025 (Outsourcing Facilities Association v. FDA).
- ▸Eli Lilly has filed civil suits against multiple compounding pharmacies and telehealth platforms including Empower, Willow, Henry Meds, and Mochi Health since April 2025.
- ▸The April 30, 2026 proposal includes tirzepatide alongside semaglutide and liraglutide, applying the same permanent-exclusion logic to the 503B bulks list.
- ▸As with semaglutide, 503A pharmacies with an individual patient prescription and documented clinical need represent the narrowest remaining legal pathway.
503A vs. 503B: What the Regulatory Difference Means Now
| 503A Pharmacy | 503B Outsourcing Facility | |
|---|---|---|
| Scale | Individual patient prescriptions only | Large batches; may ship to healthcare providers |
| FDA registration | State pharmacy board licensed | FDA-registered; subject to cGMP inspections |
| Quality standards | State-level; variable | Current Good Manufacturing Practices (cGMP) |
| GLP-1 status (2026) | Patient-specific, clinical-need only; shortage basis gone | Large-scale compounding unlawful; April 2026 proposal would formalize permanent exclusion |
| Requirement for GLP-1 | Individual Rx + documented clinical need (not cost) | No lawful basis without shortage or bulks list inclusion |
Clinical Need vs. Cost Need: Why the Distinction Matters
The FDA's April 30, 2026 proposal explicitly draws this line. Under federal compounding law, an outsourcing facility may only compound when there is documented clinical need that the commercial product cannot meet. Cost savings do not constitute clinical need.
- Clinical need (may qualify):Patient allergy to an inactive ingredient in the brand product; a dose or concentration not commercially available; a route of administration not offered by the brand.
- Cost need (does not qualify):Patient cannot afford brand-name pricing; insurance does not cover the medication; compounded version is cheaper. These are real financial hardships but they are not a legal basis for compounding under current FDA interpretation.
Regulatory Update: April 30, 2026
The FDA published a proposed rule to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. FDA Commissioner Marty Makary stated: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need."
The public comment period closes June 29, 2026. If finalized, 503B compounding of these drugs would be permanently foreclosed regardless of future shortage declarations. 503A patient-specific compounding with documented clinical need would remain the only remaining pathway.
Brand Names vs. Compounded: What's Actually Different?
At the molecular level, compounders aim to use the same active ingredient. The differences lie in everything around the molecule:
| Brand-Name | Compounded | |
|---|---|---|
| FDA approval | ✅ Yes — full NDA | ❌ No |
| Clinical trial data | ✅ Phase 2/3 trials | ❌ None on formulation |
| Purity verification | ✅ Standardized batch testing | ⚠ Varies by pharmacy |
| Inactive ingredients | Standardized, FDA-reviewed | May differ — no review |
| Dosing accuracy | Pen-auto-measured | Often drawn by syringe; error risk |
| Adverse event reporting | Mandatory pharmacovigilance | Voluntary, inconsistent |
| Examples | Wegovy, Ozempic (sema); Zepbound, Mounjaro (tirz) | Compounded semaglutide/tirzepatide vials |
One key practical difference: brand-name GLP-1s come in pre-filled auto-injector pens where the dose is set by the manufacturer. Compounded versions typically come in multi-dose vials that patients draw into syringes — introducing more potential for dosing errors.
Additionally, some compounders have added additives like B12 or other compounds to their formulations. These are not present in the FDA-approved products and have not been studied for safety or interaction effects.
Cost Comparison
The cost gap is the central reason compounded GLP-1s became so popular. Here's how the numbers break down:
| Option | Monthly Cost | Notes |
|---|---|---|
| Wegovy (2.4 mg brand) | ~$1,349 | List price; insurance may cover |
| Wegovy HD (7.2 mg brand) | ~$1,500+ | Newly approved March 2026 |
| Ozempic (off-label weight loss) | ~$935 | Diabetes-approved; often not covered for weight loss |
| Zepbound (tirzepatide brand) | ~$1,059 | Eli Lilly's weight loss formulation |
| Compounded semaglutide | $200–$400 | Telehealth platforms; 503A/503B |
| Compounded tirzepatide | $250–$500 | More widely available in 2026 than sema |
Insurance and savings options for brand-name GLP-1s:
- Many commercial insurance plans now cover Wegovy for obesity (BMI ≥30 or ≥27 with comorbidities)
- Novo Nordisk and Eli Lilly both offer patient savings programs — check manufacturer websites
- The TrumpRx initiative announced in 2025 aims to reduce prices through manufacturer agreements
- GoodRx and discount cards can reduce costs significantly at some pharmacies
For uninsured patients, the compounded price advantage is hard to ignore. A year of brand-name Wegovy can cost over $16,000 out-of-pocket versus $2,400–4,800 for compounded alternatives. For more cost-saving strategies, see our guides on finding the cheapest semaglutide online, how to save money on GLP-1s, and getting GLP-1 medications without insurance.
Safety & Quality Concerns
Safety concerns with compounded GLP-1s are real and documented. They don't mean compounded versions are universally dangerous — but they mean the risk calculus is meaningfully different.
Documented Safety Issues
- Adverse event reports: The FDA received hundreds of adverse event reports related to compounded semaglutide, including hospitalizations — some linked to incorrect concentrations
- Purity variation: Third-party testing of compounded semaglutide samples has found inconsistent active ingredient concentrations across batches and suppliers
- Impurities: Some samples have been found to contain semaglutide sodium instead of semaglutide acetate, which may have different pharmacological properties
- Unapproved additives: Many compounders add B12, L-carnitine, or other compounds not present in FDA-approved formulations and not studied for safety in combination
How to Reduce Risk If You Choose Compounded
- Use an FDA-registered 503B outsourcing facility rather than a smaller 503A pharmacy — higher manufacturing standards
- Request a Certificate of Analysis (CoA) showing third-party purity testing for your specific batch
- Work with a licensed prescriber who can monitor your response and any side effects
- Avoid formulations with unapproved additives (B12, L-carnitine, etc.) unless clinically indicated
Certificate of Analysis (CoA): What It Can and Cannot Tell You
A CoA from a compounding pharmacy confirms what the pharmacy tested for on a given batch. It is not equivalent to FDA batch release testing. Key limitations:
- Compounders set their own testing standards. There is no federal requirement for what impurity levels are acceptable or what tests must be run for compounded semaglutide or tirzepatide.
- Third-party testing of compounded semaglutide samples has found impurity levels ranging from trace amounts to over 80% in some cases, including formaldehyde adduct impurities and peptide dimers.
- Eli Lilly tested 10 compounded tirzepatide-B12 samples; all contained measurable impurities created by a chemical reaction between tirzepatide and vitamin B12.
- A useful CoA should show HPLC chromatogram data with peak area percentages and the testing laboratory's identity. A pass/fail statement without methodology provides limited assurance.
- Research-grade purity benchmarks for complex GLP-1 peptides are typically 98% or higher by HPLC. Samples below that threshold contain unknown byproducts whose clinical significance is unstudied.
Gray Market and International Import Risks
As domestic compounding access has narrowed, some patients have turned to online gray-market vendors or international sources. These sources carry distinct and serious risks:
- No regulatory oversight. Products sourced outside the US legal drug supply chain are not evaluated for safety, purity, or concentration by any US regulatory body.
- Counterfeit labeling. The FDA has documented fraudulent products with false pharmacy names on labels, including cases where the identified pharmacy did not actually compound the product.
- Unknown chemical form. Some internationally sourced products have been found to contain semaglutide sodium rather than semaglutide acetate, which may have different pharmacological and safety properties.
- Legal exposure. Importing prescription medications without a valid US prescription and through non-licensed channels may violate US customs and drug import laws.
- Dosing errors. Unverified concentration labeling in gray-market vials has contributed to overdose and adverse events documented in FDA MedWatch reports.
Legal Landscape
The legality of compounded GLP-1s is not a settled question — it varies by drug, timing, and geography, and is actively contested in courts.
Federal Law Framework
Under the Food, Drug & Cosmetic Act, compounding is generally permissible when a drug is on the FDA's shortage list. When a shortage is resolved, the basis for bulk compounding disappears. The FDA can then pursue enforcement actions against pharmacies continuing to produce the drug at scale.
Semaglutide (May 2026 status)
- ⚠Shortage resolved February 21, 2025. The primary legal basis for compounding expired at that date.
- ⚠503B enforcement discretion windows have closed. Large-scale outsourcing facility compounding from bulk is unlawful.
- ⚠Legal challenges by the Outsourcing Facilities Association were rejected at the district court level.
- ⚠503A state-licensed pharmacies retain a narrow pathway for patient-specific compounding where documented clinical need is established. Cost alone is not sufficient justification.
- ⚠April 30, 2026 FDA proposal would permanently exclude semaglutide from the 503B bulks list. Comment period closes June 29, 2026.
Tirzepatide (May 2026 status)
- ⚠Shortage resolved October 2024. The 503B enforcement-discretion period ended March 19, 2025.
- ⚠Federal court upheld the FDA's shortage removal in Outsourcing Facilities Association v. FDA, May 2025. The legal basis for bulk compounding is gone.
- ⚠Eli Lilly filed civil suits against multiple compounders including Empower, Willow, Henry Meds, and Mochi Health beginning April 2025. FDA has issued more than 135 warning letters to compounders and telehealth platforms.
- ⚠503A patient-specific compounding with documented clinical need is the only remaining narrow pathway, subject to state pharmacy law.
- ⚠April 30, 2026 FDA proposal would permanently exclude tirzepatide from the 503B bulks list alongside semaglutide and liraglutide.
State-Level Variation
Compounding is also regulated at the state level by boards of pharmacy. Some states have stricter oversight than federal minimums; others are more permissive. A compounding pharmacy legal in one state may not meet standards in another. Always verify that any pharmacy you use is licensed in your state.
Telehealth Access: How People Get Compounded GLP-1s
The typical pathway for compounded GLP-1s runs through telehealth platforms that partner with compounding pharmacies. These platforms made compounded semaglutide and tirzepatide widely accessible:
Hims & Hers
One of the largest telehealth platforms offering compounded GLP-1s. Faced significant legal challenges when FDA moved against compounders in 2025.
Ro (Roman)
Launched a compounded semaglutide program that grew rapidly. Has adjusted offerings as regulatory landscape has evolved.
Found
Focuses on medically supervised weight management, offering both compounded and, where available, brand-name options.
Henry Meds
Telehealth platform focused on metabolic health, including GLP-1 prescriptions through partnered pharmacies.
LifeMD / Trtl Health
Broader telehealth platforms with weight management tracks that have offered compounded GLP-1s.
Who Should Consider Each Option?
Brand-Name GLP-1s Are Likely Better If:
- You have insurance coverage that brings the cost down significantly
- You want FDA-reviewed quality assurance and standardized dosing
- You have cardiovascular disease — clinical trial benefit data applies to brand formulations
- You value the auto-injector pen device over drawing from a vial
- You prefer maximum legal clarity about your medication source
- You're working with a traditional physician or endocrinologist
Compounded GLP-1s Are Sometimes Considered When:
- You have no insurance coverage and brand prices are genuinely unaffordable
- You've been waiting months for brand-name supply to become available
- You're accessing a tirzepatide compound while shortage status still permits it
- You use a reputable 503B facility and can obtain Certificate of Analysis
- You're being monitored by a licensed provider who can adjust dosing
- You understand and accept the quality and legal risks involved
The Emerging Option: Oral GLP-1s
Two developments are creating new alternatives to the brand-vs-compounded binary:
- Oral semaglutide (Rybelsus): FDA-approved for weight management as of January 2026 — an injectable-free brand-name option, though typically more expensive than compounded injections
- Orforglipron (Foundayo):The first oral small-molecule GLP-1 agonist. Unlike peptide-based GLP-1s, it cannot be compounded — it's a synthetic small molecule. FDA-approved in 2026. See our orforglipron guide for details
Frequently Asked Questions
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved. The active ingredient (semaglutide) is FDA-approved in brand-name products like Wegovy and Ozempic, but compounded versions have not undergone FDA review for safety, efficacy, or manufacturing quality.
Why is compounded semaglutide so much cheaper?
Compounding pharmacies do not conduct clinical trials, seek FDA approval, or pay for branded marketing. They manufacture from bulk active pharmaceutical ingredients. Brand prices reflect R&D investment, clinical trial costs, and patent-protected status.
Is compounded semaglutide safe?
Quality varies widely. Compounded versions from FDA-registered 503B outsourcing facilities have stricter quality standards than standard 503A pharmacies. There are no published clinical trials on compounded semaglutide formulations, and the FDA has received adverse event reports, including from patients who received incorrect concentrations.
Can I still get compounded semaglutide in 2026?
Large-scale compounded semaglutide is no longer legally available through 503B outsourcing facilities since the shortage was resolved in February 2025. A narrow 503A pathway still exists for patient-specific compounding where documented clinical need is established -- such as an allergy to an inactive ingredient -- but cost is not a qualifying reason under current FDA guidance. A proposed FDA rule published April 30, 2026 would permanently exclude semaglutide from the 503B bulks list if finalized. Tirzepatide is in the same position: shortage resolved October 2024, 503B pathway closed March 2025, and also included in the April 30, 2026 proposed permanent exclusion.
What is a 503B pharmacy?
503B outsourcing facilities are large-scale compounding pharmacies registered with the FDA. They must comply with Current Good Manufacturing Practices (cGMP), undergo FDA inspections, and provide sterility and quality testing. They represent the higher-quality end of the compounding spectrum.
Does compounded semaglutide work as well as Wegovy?
Theoretically yes, if the formulation is identical. But there is no clinical trial data on compounded formulations specifically. The inactive ingredients, concentration accuracy, and formulation can all affect absorption and tolerability. Most patients report similar effects, but the evidence base supporting brand-name products does not formally extend to compounded versions.
What should I ask a compounding pharmacy before ordering?
Ask: (1) Are you a 503A or 503B facility? (2) Can you provide a Certificate of Analysis (CoA) for the specific batch? (3) What testing do you use for purity and concentration? (4) Is semaglutide acetate used (not sodium)? (5) Are any additives included and why? (6) Are you licensed in my state?
Sources
- 1.FDA. "FDA Updates on GLP-1 Drug Shortages." FDA.gov. Various updates 2023-2026.
- 2.FDA. "Compounding and the FDA: Questions and Answers." FDA.gov.
- 3.FDA. "FDA Takes Action Against Compounding of Semaglutide." MedWatch Safety Alerts, 2025.
- 4.FDA. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List." FDA.gov. April 30, 2026.
- 5.FDA. "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize." FDA.gov. 2025.
- 6.Alliance for Pharmacy Compounding. "503A vs 503B Pharmacies: Key Differences." APC, 2024.
- 7.Novo Nordisk. "Wegovy (semaglutide) Prescribing Information." 2024.
- 8.Eli Lilly. "Zepbound (tirzepatide) Prescribing Information." 2024.
- 9.Orrick. "FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs." May 2026.
- 10.Pharmacy Times. "FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding." 2025.
- 11.Outsourcing Facilities Association v. FDA. U.S. District Court. May 7, 2025.
- 12.JAMA Internal Medicine. "Analysis of Compounded GLP-1 Receptor Agonists and Adverse Events." 2025.
- 13.FDA MedWatch. Adverse event reports related to compounded semaglutide and tirzepatide products. 2024-2026.
- 14.CNBC. "FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list." April 30, 2026.